Searchable abstracts of presentations at key conferences in endocrinology

ea0038oc6.3 | Advances in reproduction and signalling | SFEBES2015

Mutations in HS6ST1 are causal in self-limited delayed puberty as well as idiopathic hypogonadotropic hypogonadism

Howard Sasha , Poliandri Ariel , Storr Helen , Metherell Louise , Cabrera Claudia , Barnes Michael , Warren Helen , Wehkalampi Karoliina , Guasti Leo , Dunkel Leo

Background: Self-limited delayed puberty (DP) often segregates in an autosomal dominant pattern, suggesting that inheritance is conferred by a small number of genes. However, the underlying genetic background is mostly unknown. By comparison, many genes have been identified where loss-of-function mutations lead to hypogonadotropic hypogonadism (HH). Despite likely overlap between the pathophysiology of delayed puberty and conditions of GnRH deficiency, few studies have examine...

ea0036P11 | (1) | BSPED2014

The accuracy of 24-h urinary free cortisol as a screening test in the diagnosis of Cushing's syndrome in children

Shapiro Lucy , Elahi Shezan , Bailey Joe , Martin Lee , Drake William M , Savage Martin O , Storr Helen L

Background: Endogenous Cushing’s syndrome (CS) in children remains a challenge to diagnose and exclude. 24-h urinary free cortisol (UFC) measurements are a convenient, non-invasive test for paediatric patients.Objective: To assess the screening accuracy of 24-h UFC measurements in paediatric patients referred to our centre for evaluation of possible CS.Methods: A retrospective review of children referred to our centre between ...

ea0058oc5.7 | Oral Communications 5 | BSPED2018

A novel GHR pseudoexon mutation causing frameshift and severe postnatal growth failure

Cottrell Emily , Maharaj Avinaash , Chatterjee Sumana , Grandone Anna , Cirillo Grazia , Miraglia del Giudice Emanuele , Metherell Louise A , Storr Helen L

Background: Growth Hormone Insensitivity is usually caused by mutations in the Growth Hormone receptor (GHR). Patients present with short stature, high GH levels, low IGF-I levels and typical Laron syndrome facial features. Our centre previously described the first GHR pseudoexon mutation (42700896A>G, c.618+792A>G). The inclusion of this pseudoexon is predicted to cause in-frame insertion of 36 amino acid residues between exons 6 and 7. This insertion in the ...

ea0034p158 | Growth and development | SFEBES2014

A novel gene affecting the timing of puberty

Howard Sasha , Guasti Leo , Storr Helen , Metherell Lou , Cariboni Anna , Barnes Michael , Cabrera Claudia , Wehkalampi Karoliina , Dunkel Leo

Background: Disturbances of pubertal timing affect >4% of the population and are associated with adverse health outcomes. Studies estimate 60–80% of variation in pubertal onset is genetically determined, but few genetic factors are known. We hypothesise that causal variants will be low-frequency, intermediate-impact variants and will be enriched in populations at the extremes of normal pubertal timing. Families with constitutional delay in growth and puberty (CDGP) ha...

ea0030oc1.3 | Oral Communications 1 | BSPED2012

Potential novel insights into the control of the feto-placental unit by kisspeptin

Katugampola Harshini , Dunkel Leo , King Peter J , Achermann John A , Duncan Andrew J , Sankilampi Ulla , Storr Helen L

Introduction: Kisspeptin is the endogenous ligand for the G-protein coupled receptor-54 (GPR54 or KiSS1R). During human pregnancy, maternal levels of placental kisspeptin dramatically increase 7000-fold. The physiological significance of this is unknown. A potential target could be the fetal adrenal cortex (FAC), which undergoes rapid growth from 10 weeks gestation, predominantly of the inner fetal zone (FZ). The FZ expresses the steroidogenic enzymes needed for conversion of ...

ea0030p2 | (1) | BSPED2012

Outcome of endoscopic transsphenoidal pituitary surgery in four paediatric Cushing's disease patients: a new therapeutic approach

Storr Helen L , Drake William M , Akker Scott A , Monson John P , Savage Martin O , Alusi Ghassan , Sabin H Ian

Selective transsphenoidal adenomectomy remains the accepted first line treatment for Cushing’s disease (CD), until recently by microscopic (sublabial) transsphenoidal pituitary surgery. Endonasal transsphenoidal endoscopic surgery is emerging as a novel, less invasive treatment for pituitary adenomas with lower postoperative complications and morbidity. The safety of endoscopic surgery has been extensively reviewed in adult patients and is now considered best practice for...

ea0095p147 | Pituitary and Growth 2 | BSPED2023

Testing a screening algorithm for the identification of growth-disorders for use in UK children

Orr Joanna , Thaventhiran Thilipan , Freer Joseph , Walton Robert , Morris Joan K , Dunkel Leo , Prendergast Andrew J. , Storr Helen L.

Background: Screening algorithms for the identification of growth-disorders are routinely used in several countries. In the UK, the use of the Coventry consensus for the referral of children with suspected growth-disorders performs poorly compared to more sophisticated screening mechanisms used elsewhere. We aimed to test an algorithm developed to screen for growth-disorders in 2- to 8-year-old UK children.Methods: The a...

ea0051oc5.6 | Oral Communications 5 | BSPED2017

Phenotypic spectrum and response to recombinant human IGF1(rhIGF1) therapy in patients with homozygous intronic pseudoexon ()GH receptor mutations

Chatterjee Sumana , Rose Stephen , Mushtaq Talat , Clayton Peter , Ten Svetlana , Bhangoo Amrit , Kumbattae Uma , Dias Renuka , Shapiro Lucy , Metherell Louise , Savage Martin , Storr Helen

Objectives: Patients with homozygous 6Ψ mutations have GH insensitivity (GHI). We previously described spectrum of clinical and biochemical phenotypes of 11 6Ψ patients (David et al. JCEM 2007;92:655) and now report 9 additional patients. Response to rhIGF-I therapy has not previously been assessed.Methods: 20 6Ψ patients (12 M, 11 families, mean age 4.0±2.2 year) were diagnosed genetically in our centre. Continuous ...

ea0051p002 | Thyroid | BSPED2017

Radioactive Iodine therapy for the management of hyperthyroidism in children and adolescents

Wilkinson Ingrid C E Wilkinson , Meso Muriel , Rowse Victoria , Joel Emily , Morris Elizabeth , Price Leanne , Storr Helen L , Drake William M

Background: Radioactive iodine therapy (RAI) is established as a safe and effective treatment for adults with Grave’s disease. As thyrotoxicosis in children is rare, it is difficult to obtain high quality evidence about the safety and efficacy of RAI. We present data from our centre between 2007 and 2017.Methods: 20 paediatric patients with hyperthyroidism (16F), median age 15.7 years (range 10.8–19.3) had RAI in our centre either one or two do...

ea0066oc4.7 | Oral Communications 4 | BSPED2019

Novel variants in the Leucine-zipper-like transcription regulator 1 (LZTR1) gene cause Noonan syndrome phenotype by upregulation of the RAS-MAPKinase pathway

Chatterjee Sumana , Bertola Debora , Agwu Chizo , Karantza Maria , Cottrell Emily , Shapiro Lucy , Maharaj Avinaash V , Williams Jack , Savage Martin O , Gaston-Massuet Carles , Metherell Louise A , Storr Helen L

Objectives: Noonan Syndrome (NS) is an autosomal dominant multi-system disorder characterised by short stature (SS), distinctive facial features and cardiovascular abnormalities. Mutations in multiple genes regulating the RAS-MAPK pathway have been identified in NS including 5 recently described novel LZTR1 variants. We identified 2 novel LZTR1 variants in patients with features of growth hormone insensitivity and NS. The molecular function of LZTR1 ...